Breast Cancer in Women: Epidemiological, Histological, Immunohistochemical and Molecular Sub-Types in the Republic of Congo

Malanda, Dimitry Moudiongui Mboungou; Boumba, Anicet Luc Magloire; Malonga, Gervillien Arnold

doi:10.52403/ijhsr.20210515

Cited by 4 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moderately differentiated (grade II) BC was found in most (49.6%) patients. This result agreed with other studies conducted by Gemta et [13,25,27,[30][31][32][33][34][35][36][37]. Conversely, poorly differentiated (grade III) BC was common in another study conducted in Ghana (49%) [30].…”

Section: Clinicopathological Featuressupporting

confidence: 91%

“…Moderately differentiated (grade II) BC was found in most (49.6%) patients. This result agreed with other studies conducted by Gemta et al, Hadi and Jamal, Takalkar et al, Pathak et al, Toma et al, Malanda et al, Adeniji et al, Ezike et al, Zilenaite et al, Uyisenga et al and Maffuz-Aziz et al, who reported 46.2%, 47.3%, 75.4%, 76.8%, 53.8%, 51,3%, 52.6%, 59.5%, 46.5%, 52.9%, and 54.1% of grade II tumor, respectively [ 13 , 25 , 27 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ]. Conversely, poorly differentiated (grade III) BC was common in another study conducted in Ghana (49%) [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological Features of Invasive Breast Cancer: A Five-Year Retrospective Study in Southern and South-Western Ethiopia

Belachew,

Desta,

Deneke

et al. 2023

Medicines

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common type of cancer in Ethiopia. The incidence of BC is also rising, but the exact figure is still poorly known. Therefore, this study was conducted to address the gap in epidemiological data on BC in southern and southwestern Ethiopia. Materials and Methods: This is a five-year (2015–2019) retrospective study. The demographic and clinicopathological data were collected from biopsy reports of different kinds of breast carcinomas in the pathology department of Jimma University Specialized Hospital and Hawassa University Specialized Referral Hospital. Histopathological grades and stages were conducted using Nottingham grading and TNM staging system, respectively. Collected data were entered and analyzed using SPSS Version-20 software. Results: The mean age of patients at diagnosis was 42.27 (SD = 13.57) years. The pathological stage of most BC patients was stage III, and most of them had tumor sizes greater than 5 cm. Most patients had moderately differentiated tumor grade, and mastectomy was the most common type of surgery at the time of diagnosis. Invasive ductal carcinoma was the most common histological type of BC, followed by invasive lobular carcinoma. Lymph node involvement was seen in 60.5% of cases. Lymph node involvement was associated with tumor size (χ2 = 8.55, p = 0.033) and type of surgery (χ2 = 39.69, p < 0.001). Conclusions: This study showed that BC patients in southern and southwestern Ethiopia displayed advanced pathological stages, relatively young age at diagnosis, and predominant invasive ductal carcinoma histological patterns.

show abstract

Section: Clinicopathological Featuressupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features of Invasive Breast Cancer: A Five-Year Retrospective Study in Southern and South-Western Ethiopia

Belachew,

Desta,

Deneke

et al. 2023

Medicines

View full text Add to dashboard Cite

show abstract

“…The findings regarding the impact of family history align with recent studies, which reported a similar trend. The study by Mboungou Malanda et al [35] noted that only 11 cases, accounting for 7.33%, had a family history of breast cancer. Likewise, another study by Gautam et al [36] found that 10.4% of patients had a family history of breast cancer, while the majority, 89.6%, had no family history of breast cancer.…”

Section: F Family History Distributionmentioning

confidence: 99%

Estimation of gene expression level of CDH1 as a predisposing factor for metastasis in localized and locally advanced and metastatic breast cancer Iraqi patients

Abdallah,

Aziz,

Alsammarraie

2023

Trends Immunother.

View full text Add to dashboard Cite

Breast cancer (BC) is a prevalent malignancy among women, ranking as the second most commonly diagnosed cancer globally. Notably, a substantial proportion of breast cancer-related fatalities, up to 90 percent, are attributed to the development of distant organ metastases. While Cadherin1 (CDH1) has conventionally been considered a tumor-suppressor gene in cancer research, recent investigations have unequivocally revealed that both CDH1 and its encoded E-cadherin exhibit oncogenic characteristics. The primary focus of this case-control study is to ascertain the involvement of the CDH1 gene in a specific subset of Iraqi female patients. A total of ninety patients sought diagnosis and treatment at the Oncology Teaching Hospital in Medical City and the Oncology Unit at Al-Yarmouk Teaching Hospital in Baghdad. In addition, we included 30 apparently healthy individuals as blood control subjects and another 30 women with benign breast tumors as tissue control subjects for the study. In the initial phase of the study, we conducted a serological analysis using enzyme-linked immunosorbent assay (ELISA) to detect the concentration of E-cadherin in serum samples from two groups of BC patients. The group with locally advanced and metastatic BC exhibited a significantly higher E-cadherin concentration (963.4 ± 89.8 pg/mL) compared to the group with localized BC. In the second part of the research, qRT-PCR was performed to analyze the expression of the CDH1 gene across all sample types. CDH1 was shown to have the greatest fold expression (2.550 ± 0.164) in cases with locally progressed and metastatic BC. Compared to the seemingly healthy control group, the fold expression for localized BC was 1.456 ± 0.055, and for malignant tissue it was 1.886 ± 0.08621. In conclusion, this study provides compelling evidence supporting CDH1 as an oncogene in BC. The significance of CDH1 in BC tumorigenesis underscores its potential for the development of novel detection biomarkers and targeted therapeutic approaches for BC treatment. Notably, CDH1 exhibited elevated expression levels in BC tissues and demonstrated an association with an unfavorable distant metastasis-free survival outcome.

show abstract

Histopathological profile of triple negative breast carcinomas seen in patients in National Hospital, Abuja over a 10-year period (January 2010-December 2019)

Benye,

Jibrin,

Achusi

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Triple negative breast carcinoma (TNBC) cases in Africa and the black race which are most commonly seen among the reproductive age group are highly aggressive and have a high mortality rate. Based on its protein expression using immunohistochemical methods it does not express the hormone receptors (oestrogen and progesterone) and the human epidermal growth factor receptor 2 (HER2). As a result the only means of treating TNBC patients so far is by conventional chemotherapy +/- radiotherapy. Even then only 50.0 % of these patients will respond to the chemotherapy. Further studies which may help improve treatment and survival in these patients are important. Objective: This study is aimed at knowing the histopathological profile of TNBCs in Abuja with the expression of androgen receptor; an important marker in these patients. Method: Two hundred formalin-fixed paraffin embedded TNBC tissue blocks were selected for the study. The histological type and their respective histological grades (based on the Nottingham grading system) were noted from the haematoxylin and eosin(H&E) sections. Immunohistochemical staining was done using antibodies against androgen receptor (Biocare) and CK5/6 (Invitrogen) with in-house controls. The androgen receptor and CK5/6 expressions were analysed using a semi-quantitative scoring method: -A tumour was considered positive for LAR if ≥ 1.0 % of tumour cell nuclei were staining and positive for CK5/6 if ≥10.0 % of tumour cells had membrane staining. Other biographic data like tumour size, presence or absence of lymphovascular permeation were also analysed. Correlation between the histological types and grades were also done using SPSS version 21 statistical package. Results: The 30-49 age group had the highest frequency of TNBC. The commonest histological type seen among TNBCs is Invasive carcinoma; NST at 93.0%. The most frequent histological grade is grade 2 at 56.0 %. The androgen receptor subtype constituted 19.0 %. The basal subtype formed 28.5 % of the total sample size. There was no significant correlation between the histological type and grade of TNBC. 73.3% of the patients had tumour size of pT1 and pT2. Conclusion: This study shows that the percentage of androgen positive cases among triple negative breast carcinomas is significant enough to warrant routine luminal AR testing for TNBCs. Furthermore, this study has shown that the most frequent histological type is Invasive carcinoma; Non-specific type (NST) regardless of the molecular subtype and presence or absence of lympho-vascular permeation. It has also shown that the most frequent histological grade seen among patients with TNBCs is Grade 2.

show abstract

Breast Cancer in Women: Epidemiological, Histological, Immunohistochemical and Molecular Sub-Types in the Republic of Congo

Cited by 4 publications

References 37 publications

Clinicopathological Features of Invasive Breast Cancer: A Five-Year Retrospective Study in Southern and South-Western Ethiopia

Clinicopathological Features of Invasive Breast Cancer: A Five-Year Retrospective Study in Southern and South-Western Ethiopia

Estimation of gene expression level of CDH1 as a predisposing factor for metastasis in localized and locally advanced and metastatic breast cancer Iraqi patients

Histopathological profile of triple negative breast carcinomas seen in patients in National Hospital, Abuja over a 10-year period (January 2010-December 2019)

Contact Info

Product

Resources

About